Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone.
To assess short-term efficacy and safety of intravitreal bevacizumab injections for idiopathic choroidal neovascularization (CNV) refractory to posterior subtenon triamcinolone injections. Noncomparative, interventional case series. Intravitreal bevacizumab was injected into 10 eyes with idiopathic CNV in which posterior subtenon triamcinolone injections were not efficacious for more than three months. The main outcome measures were changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and fluorescein angiography findings before and after bevacizumab injection. After treatment, the BCVA improvement at one month (P = .029) continued to three months (P = .003). CRT decreased significantly (P < .001). Leakage from idiopathic CNV three months after treatment stopped in seven eyes, decreased in two, and continued in one. In one patient, conjunctival swelling developed after the injection but resolved and did not recur after another injection. No other complications developed. Intravitreal bevacizumab improves BCVA in eyes with idiopathic CNV refractory to triamcinolone.